Related Experiment Videos
New Gram-positive agents in nosocomial infection
1Department of Medicine/Infectious Diseases, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
Abstract:
Multidrug-resistant Gram-positive pathogens such as vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and methicillin-resistant coagulase-negative staphylococci account for a significant number of nosocomial infections, and new options for therapy have been lacking. During the past year, two agents have been released that have activity against these organisms: quinupristin/dalfopristin and linezolid. Although neither agent is a panacea, these recently released agents offer new options for therapy.
Insights
New antibiotics quinupristin/dalfopristin and linezolid offer crucial treatment options for serious Gram-positive bacterial infections. These agents combat multidrug-resistant pathogens, addressing a critical gap in nosocomial infection therapy.
Area of Science:
- Infectious Diseases
- Microbiology
- Pharmacology
Background:
- Nosocomial infections frequently involve multidrug-resistant Gram-positive pathogens.
- Notable examples include vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and methicillin-resistant coagulase-negative staphylococci.
- Therapeutic options for these resistant infections have been limited.
Purpose of the Study:
- To introduce and discuss two new therapeutic agents with activity against multidrug-resistant Gram-positive pathogens.
- To highlight the significance of these agents in addressing the unmet need for effective treatments.
Main Methods:
- Review of recently released antimicrobial agents.
- Assessment of their spectrum of activity against key Gram-positive pathogens.
- Clinical relevance and therapeutic potential evaluation.
Main Results:
- Two new agents, quinupristin/dalfopristin and linezolid, have been introduced.
- Both agents demonstrate activity against challenging multidrug-resistant Gram-positive organisms.
- These represent significant advancements in treatment options.
Conclusions:
- Quinupristin/dalfopristin and linezolid provide valuable new therapeutic avenues.
- While not universally effective, they offer hope against resistant Gram-positive infections.
- These agents are important additions to the clinical armamentarium for nosocomial infections.